pubrio
SanegeneBio

SanegeneBio

United States · Biotechnology Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Biotechnology Research

Sanegene Bio is a clinical-stage, fully integrated biotechnology company backed by a syndicate of private equity investors. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is headquartered in Boston, with R&D operations in both the U.S. and China. Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.

Company Insights
Company Overview

2021

Founded

Biotechnology Research

Industry

United States

Location

13,207,211

Ranking

23 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding SanegeneBio

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​